Susquehanna International Group’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,158
| Closed | -$12.9K | – | 6451 |
|
|
2024
Q4 | $12.9K | Buy |
2,158
+20
| +0.9% | +$120 | ﹤0.01% | 6030 |
|
|
2024
Q3 | $20.9K | Sell |
2,138
-8,694
| -80% | -$84.9K | ﹤0.01% | 5401 |
|
|
2024
Q2 | $222K | Buy |
10,832
+5,195
| +92% | +$106K | ﹤0.01% | 4600 |
|
|
2024
Q1 | $254K | Buy |
+5,637
| New | +$254K | ﹤0.01% | 4400 |
|
|
2023
Q4 | – | Sell |
-1,216
| Closed | -$49.2K | – | 5980 |
|
|
2023
Q3 | $49.2K | Sell |
1,216
-14,471
| -92% | -$586K | ﹤0.01% | 5125 |
|
|
2023
Q2 | $1.67M | Buy |
15,687
+11,813
| +305% | +$1.26M | ﹤0.01% | 2104 |
|
|
2023
Q1 | $1.16M | Buy |
3,874
+2,610
| +206% | +$779K | ﹤0.01% | 2682 |
|
|
2022
Q4 | $435K | Sell |
1,264
-1,995
| -61% | -$686K | ﹤0.01% | 3419 |
|
|
2022
Q3 | $616K | Sell |
3,259
-1,722
| -35% | -$325K | ﹤0.01% | 3235 |
|
|
2022
Q2 | $1.05M | Sell |
4,981
-2,794
| -36% | -$590K | ﹤0.01% | 2393 |
|
|
2022
Q1 | $2.6M | Sell |
7,775
-3,339
| -30% | -$1.12M | ﹤0.01% | 1741 |
|
|
2021
Q4 | $3.62M | Sell |
11,114
-3,838
| -26% | -$1.25M | ﹤0.01% | 1449 |
|
|
2021
Q3 | $7.26M | Buy |
14,952
+1,540
| +11% | +$748K | ﹤0.01% | 933 |
|
|
2021
Q2 | $6.24M | Buy |
13,412
+1,519
| +13% | +$706K | ﹤0.01% | 1095 |
|
|
2021
Q1 | $8.21M | Buy |
11,893
+2,360
| +25% | +$1.63M | ﹤0.01% | 909 |
|
|
2020
Q4 | $7.05M | Sell |
9,533
-4,870
| -34% | -$3.6M | ﹤0.01% | 824 |
|
|
2020
Q3 | $9.99M | Buy |
14,403
+14,160
| +5,827% | +$9.82M | ﹤0.01% | 525 |
|
|
2020
Q2 | $206K | Buy |
+243
| New | +$206K | ﹤0.01% | 3684 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 4566 |
|